FTC v. Endo Pharmaceuticals Inc., et al

  1. August 25, 2023

    DC Circ. Won't Revive FTC's Endo-Impax Deal Suit

    A D.C. Circuit panel refused Friday to revive a Federal Trade Commission lawsuit targeting an opioid medication settlement between Endo Pharmaceuticals and Impax, concluding the license brandmaker Endo granted for Impax to sell a generic, even the only version of the drug available, was just "a standard exclusive license."

  2. May 01, 2023

    DC Circ. Asks What's Wrong With Endo-Impax Deal

    A D.C. Circuit panel questioned an attorney for the Federal Trade Commission on Monday about what makes a 2017 settlement between Endo Pharmaceuticals and Impax over an opioid medication that the agency is challenging different from "garden variety" patent licensing agreements.

  3. March 17, 2023

    FTC Urges DC Circ. Not To Prolong Endo-Impax Monopoly

    The Federal Trade Commission urged the D.C. Circuit not to push back oral argument for the agency's bid to revive a case accusing Endo and Impax of splitting monopoly profits for a lucrative opioid, contending that the alleged conduct needs to be stopped now.

  4. December 22, 2022

    DC Circ. Urged To Overturn Endo-Impax Opioid Deal Win

    The Federal Trade Commission urged the D.C. Circuit to overturn a lower court's decision that allowed two pharmaceutical companies to continue an alleged pay-for-delay agreement, arguing that the companies are still subject to antitrust scrutiny even if the agreement was an exclusive patent license.

  5. October 28, 2022

    Celsius Network Gets OK To Auction, GWG To Raise Money

    Crypto lender Celsius Network got the go-ahead to auction off its assets, bond seller GWG Holdings got permission to raise $630 million to pay back its bankruptcy loans and Axos Bank was hit with an $18.3 million verdict for pilfering MUFG Union Bank's Chapter 7 trustee deposit business. This is the week in bankruptcy.

  6. October 24, 2022

    DC Circ. Restarts FTC's Endo Appeal Despite Ch. 11

    The D.C. Circuit on Monday resumed briefing on Federal Trade Commission antitrust claims against Endo Pharmaceuticals Inc. after the FTC argued Endo's Chapter 11 filing didn't require the court to halt the appellate case.

  7. September 08, 2022

    FTC Says Endo Bankruptcy Can't Stop DC Circ. Appeal

    The Federal Trade Commission has asked the D.C. Circuit to lift a bankruptcy-related stay in its bid to revive antitrust claims accusing Endo Pharmaceuticals Inc. of entering a "pay-for-delay" agreement with Impax Laboratories LLC to stave off competition to Endo's Opana ER painkiller.